Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

21results about How to "Increased activation" patented technology

CD8 antibody modified anti-TIM-3 lipid nanoparticle, preparation method and application thereof

The invention provides a CD8 antibody modified anti-TIM-3 lipid nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of medical preparations. The lipid nanoparticle contains a chimeric antigen receptor; the chimeric antigen receptor comprises a single-chain antibody TIM-3; the nucleic acid artificial sequence of the single-chain antibody TIM-3 is as shown in SEQ ID NO. 5. According to the application, sequence optimization is carried out on a TIM-3 target spot, a CAR structure connected with a double-stimulating factor and a suicide gene is prepared, and anti-TIM-3 nano-lipid particles modified by a CD8 antibody are constructed and delivered into cells, so that CD8 + T cells can be effectively captured in a body, CAR-T cells can be generated, a complex process of in-vitro preparation is omitted, and the application has the advantages of simplicity, convenience in operation and high efficiency. The activation degree of T cells is improved while the antigen is efficiently recognized, the efficient anti-tumor effect is achieved, the survival time of breast cancer mice is obviously prolonged, and the growth of tumors is inhibited.
Owner:SHANDONG RES INST OF ADULT CELL IND TECH CO LTD

METHODS TO IMPROVE THE EFFICACY AND EXPANSION OF IMMUNE CELLS

ActiveIT202600039718T2altering phenotypeIncreased activationEfficacyParticle physics
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

High-performance composite current collector and preparation method thereof

The invention relates to the technical field of battery current collectors, and discloses a high-performance composite current collector, which comprises a base film and a metal layer on at least one side of the base film, the base film is prepared from the following raw material components in parts by weight: 65 to 95 parts of PET (Polyethylene Terephthalate), 2 to 25 parts of PET grafted polyaniline, 0.2 to 5 parts of graphene oxide, 0.1 to 5 parts of a coupling agent, 1 to 5 parts of maleic anhydride grafted PET and 1 to 5 parts of imide modified PET. By adopting the composite current collector provided by the invention, the balance, the thermal decomposition temperature and the flame-retardant capability of the current collector can be improved.
Owner:SHIPU LISTED POLYMER NEW MATERIALS CO LTD

Improved peptide vaccine

It is an object of the present invention to provide a peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells. It is another object of the present invention to provide a method for delivering a peptide vaccine specifically to the surface of specific immune cells. As a result of diligent studies, the inventors of the present invention have shown that the aforementioned objects can be achieved by providing a peptide vaccine combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells (e.g., dendritic cells).
Owner:BRIGHTPATH BIOTHERAPEUTICS CO LTD +1

Specific binding protein targeting pd-l1 and cd73

The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and / or a fragment thereof, and CD73 and / or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and / or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.
Owner:HARBOUR BIOMED (SHANGHAI) CO LTD

2-Heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

InactiveMA47447AInhibition of activationReduce activation
The present invention relates to 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (i), wherein x, r1, r2, r3, r4, and r5 are as defined in the description. The invention also relates to methods for preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular cancer or diseases with dysregulation of immune responses or other disorders associated with aberrant AHR signals, as monotherapy or in combination with other active ingredients.
Owner:BAYER PHARMA AG +2

Lactobacillus plantarum-derived vesicle and use thereof

InactiveEP4349351A4Increased activationavoid changeCosmetic preparationsMetabolism disorder
The present invention relates to Lactobacillus plantarum-derived vesicles and a use thereof and, more specifically, to a composition containing Lactobacillus plantarum-derived vesicles as an active ingredient for prevention, alleviation, or treatment of an immune disease or a metabolic disorder. The present inventors found that when Lactobacillus plantarum-derive vesicles were administered into an immune disease or metabolic disorder model, pathogenic factor-induced immune dysfunction and metabolite-induced metabolic dysfunction can be effectively inhibited. Thus, the Lactobacillus plantarum-derived vesicles according to the present invention are expected to find advantageous applications in the development of medical products or health function foods for preventing or treating immune diseases or metabolic disorders or for alleviating symptoms thereof.
Owner:MD HEALTHCARE INC

A perovskite solar cell and its fabrication method

ActiveCN116075163BGuaranteed photoelectric conversion efficiencyImprove uniformity
This invention provides a perovskite solar cell and its fabrication method. The fabrication method of the perovskite solar cell includes the following steps: forming a first electrode layer on one side surface of a substrate; and forming NiO on one side surface of the first electrode layer using a magnetron sputtering process. x The layer uses a nickel oxide target. During magnetron sputtering, oxygen is introduced into the magnetron sputtering chamber at a flow rate of 4.5 sccm to 15 sccm and a temperature of 100°C to 140°C. The aforementioned NiO... x The layer preparation method facilitates the doping of oxygen molecules into the nickel oxide film, thus achieving the desired oxygen doping level without the need for excessive oxygen introduction, and enabling precise control of NiO. x The oxygen content of the layer; the low oxygen content in the magnetron sputtering chamber can prevent NiO. x Excessive oxygen doping in the NiO layer ensures the photoelectric conversion efficiency of the perovskite solar cell; the aforementioned NiO x The layer preparation method also improves the uniformity of oxygen distribution within the magnetron sputtering chamber, thereby enhancing the NiO content. x The uniformity of oxygen doping in the layer improves the performance uniformity of perovskite solar cells.
Owner:WUXI UTMOST LIGHT TECH CO LTD

Methods for improving the efficacy and expansion of immune cells

ActivePT3325504Taltering phenotypeIncreased activation
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
Owner:NOVARTIS AG +1

Method for preparing low-impurity manganese sulfate solution by using manganese oxide ore as raw material

InactiveCN119082506AIncreased activationlow ion contentProcess efficiency improvementManganese sulfatesSlagHydrometallurgy
The invention relates to the technical field of hydrometallurgy, and discloses a method for preparing a low-impurity manganese sulfate solution by taking manganese oxide ore as a raw material, which comprises the following steps of: ball-milling the manganese oxide ore into powder, adding the manganese oxide ore powder into a dilute sulfuric acid aqueous solution, soaking and pickling at normal temperature, carrying out solid-liquid separation, and mixing the pickled manganese oxide ore powder with hydrated slurry to obtain a mixture; and adding the slurry into a reaction kettle, stirring, heating the slurry to 60-80 DEG C, introducing copper smelting tail gas, reacting and leaching, adding a proper amount of reduced manganese powder (MnO) and BaS into the leached slurry, and filtering to remove slag, thereby obtaining the low-impurity manganese sulfate solution. After the manganese oxide ore is subjected to ball milling, acid pickling and slurrying, the copper smelting sulfur dioxide tail gas is introduced for reduction leaching, the manganese sulfate solution containing extremely low impurity element ions such as K <->, Na < + >, Ca < 2 + > and Mg < 2 + > is prepared, the total manganese leaching rate of the manganese oxide ore is high, the process flow is short, and the production efficiency is high.
Owner:GUANGXI HUIJIN NEW ENERGY CO LTD

Preparation method of composite conductive microspheres for ACF (anisotropic conductive film)

The invention discloses a preparation method of composite conductive microspheres for ACF, and belongs to the technical field of conductive materials. Comprising the following steps: (1) preparing functionalized polymer microspheres with rough surfaces; (2) activating the microspheres obtained in the step (1) in a palladium chloride diluted hydrochloric acid solution to obtain activated microspheres; and (3) dispersing the activated microspheres in the step (2) in a chemical nickel plating solution to obtain the composite conductive microspheres. The surface of the microsphere is provided with density-adjustable amino functional groups, the microsphere and palladium ions in an activation reagent can form a stable complex, the activation degree is higher, the surface of the microsphere is rough, the microsphere and a plating layer have stronger binding force relative to a smooth surface, the obtained nickel plating layer is firmer and is not prone to falling off in the using process, and the preparation method is simple and easy to implement. The environment is protected.
Owner:GUTAI (JIANGSU) NEW MATERIALS CO LTD

Mutant ovis spp. infectious pustular dermatitis virus and use thereof

PendingEP4206327A4Improve anti-tumor effectIncreased activationVirus peptidesUnknown materials
Provided are the use of a mutant Ovis spp. infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in the treatment of cancer.
Owner:SUZHOU PRAJNA BIOTECH CO LTD

Valve timing adjustment system and electronic control device

PendingEP4379195A4Increased activationhigh viscosityValve arrangementsElectrical control
A valve timing adjustment system includes a valve timing adjustment device (1), a phase lock mechanism (2), a hydraulic control valve (3), an electromagnetic drive section (4), and an electronic control device (5). When the lock pin (50) included in the phase lock mechanism (2) and having the tip thereof fitted into a fitting recess (51) is removed from the fitting recess (51), the electronic control device performs an initial control of applying current to the electromagnetic drive section (4) at a prescribed current value for a prescribed time to move a spool (90) of the hydraulic control valve (3) from an initial position. Thereafter, the electronic control device (5) performs a gradual change control of applying current to the electromagnetic drive section (4) while gradually increasing the current value from a current value smaller than the current value applied in the initial control but greater than 0, to remove the lock pin (50) from the fitting recess (51).
Owner:DENSO CORP

ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127

ActiveMA49727Aeffective interactionIncreased activation
The invention relates to the field of antibodies useful in therapeutic and diagnostic applications targeting cd127, the alpha chain of the il7 receptor, and in particular provides humanized monoclonal antibodies against cd127, especially human cd127, their therapeutic uses and diagnostic applications.
Owner:OSE IMMUNOTHERAPEUTICS SA

A pharmaceutical composition comprising NK cells and its application in preparing a drug for treating tumors

The present invention relates to a pharmaceutical composition comprising NK cells and its application in the preparation of a drug for treating tumors. The composition comprises NK cells and a PD-L1-targeted antibody; the pharmaceutical composition further comprises an immune cytokine, which is selected from one or more of human IL-2, IL-12, IL-15, IL-18 and IL-21. Targeted PD-L1 antibodies can enhance the anti-tumor effect of NK cells, increase the survival cycle of animals, promote the secretion of anti-tumor factors, and immunomodulatory factors such as IL-2 and IL-21 can promote the proliferation of NK cells, increase the degree of activation of NK cells, and further improve the anti-tumor effect of NK cells.
Owner:ZHEJIANG SAIER GONGYIN BIOTECHNOLOGY CO LTD

Lactobacillus rhamnosus-derived vesicle and uses thereof

InactiveEP4349353A4Increased activationWeight increaseCosmetic preparationsMetabolism disorder
The present invention relates to a Lactobacillus rhamnosus-derived vesicle and uses thereof, and to a composition for preventing, alleviating, or treating immune diseases or cellular aging-related diseases, comprising a Lactobacillus rhamnosus-derived vesicle as an active ingredient. The present inventors have confirmed that a Lactobacillus rhamnosus-derived vesicle increases cellular homeostasis to suppress the occurrence of cellular aging-related diseases, and suppresses the occurrence of immune diseases by inhibiting immune hypersensitivity reactions in an immune disease model induced by viral causative factors. Accordingly, the Lactobacillus rhamnosus-derived vesicle according to the present invention may be effectively used in the development of a drug or health functional food for preventing, alleviating, or treating viral infectious diseases, allergic immune diseases, autoimmune diseases, inflammatory diseases, cellular aging-related diseases, etc.
Owner:MD HEALTHCARE INC

Culture method of DC-CTL cells

InactiveCN121975734ANo abnormal aggregationHigh differentiation efficiencyMicroencapsulation basedBlood/immune system cellsLipofectamineCell activity
The invention discloses a culture method of DC-CTL cells, and particularly relates to the technical field of biotechnology and medicine. The invention provides a novel DC-CTL cell culture method based on iPSC, aiming at the technical problems that a traditional DC-CTL cell culture method is limited in cell source, greatly influenced by individual difference, poor in stability and repeatability, insufficient in cell activity and killing ability and the like. A self-made additive and a specific cell factor are combined, SOCS1-siRNA is transfected through a liposome transfection method, the SOCS1 gene is effectively silenced, and the T cell activity is enhanced. According to the method, the proportion of CD3 + CD8 + T cells in the DC-CTL cells reaches 85% or above, the content of IFN-gamma is larger than or equal to 500 pg / mL, the content of TNF-alpha is larger than or equal to 300 pg / mL, and the killing rates under the effect target ratios of 10: 1, 20: 1 and 40: 1 reach 57%, 63% and 72% respectively.
Owner:XIAMEN SERBANGKE BIOTECHNOLOGY CO LTD

Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes

ActivePL3310815T3Enhance immune functionIncreased activation
The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
Owner:F HOFFMANN LA ROCHE & CO AG

Automatic stirrer for activating saccharomyces cerevisiae

The utility model discloses an automatic stirrer for activating saccharomyces cerevisiae, which comprises a supporting seat, an anti-caking component, a mixing component, a temperature sensor, a tank body, a heat insulation cover, a discharge valve and a snake-shaped electric heating wire. Active dry yeast is poured into the discharging hopper, enters the rotary joint and the round pipe through the discharging hopper, is discharged into the screening barrel through a group of through grooves, enters the tank body through the screening holes, is stirred by the mixing assembly through warm water, and simultaneously passes through the anti-caking assembly, so that the active dry yeast is discharged into the tank body through the screening holes. The group of scattering rods are used for scattering the active dry yeast which is in contact with warm water and is caked in the screening barrel, so that the agglomeration phenomenon of the active dry yeast is avoided, and the scattered active dry yeast gradually passes through the screening holes to be in contact with the warm water in the tank body, so that the active dry yeast is quickly and fully dissolved in the warm water; and the proper temperature can improve the activation degree, the activation quality and the activation efficiency of the active dry yeast.
Owner:QINGDAO HUADONG WINERY CO LTD

A CD8 antibody-modified anti-TIM-3 lipid nanoparticle, preparation method and application thereof

The present invention provides a CD8 antibody-modified anti-TIM-3 lipid nanoparticle, a preparation method and its application, which belongs to the technical field of medical preparations, wherein the lipid nanoparticle contains a chimeric antigen receptor; the chimeric antigen receptor includes a single-chain antibody TIM-3; the nucleic acid artificial sequence of the single-chain antibody TIM-3 is shown in SEQ ID NO.5. The present application performs sequence optimization on the TIM-3 target, prepares a CAR structure connecting a dual stimulatory factor and a suicide gene, and constructs an anti-TIM-3 nanolipid particle modified by a CD8 antibody, which is delivered to cells, can effectively capture CD8+T cells in the body, produce CAR-T cells, eliminate the complex process of in vitro preparation, and improve the activation degree of T cells while efficiently recognizing antigens, exerting a highly effective anti-tumor effect, significantly prolonging the survival of breast cancer mice, and inhibiting tumor growth.
Owner:SHANDONG RES INST OF ADULT CELL IND TECH CO LTD

Methods for improving the efficacy and expansion of immune cells

ActiveSI3325504T1altering phenotypeIncreased activation
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
Owner:NOVARTIS AG +1